p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. Wang K, Baldwin GS, Nikfarjam M, He H. World J Gastroenterol. (2018) 7:3709-3723. doi: 10.3748/wjg.v24.i33.3709. Review.

The role of p21-activated kinases in pancreatic cancer. Yeo D, He H, Baldwin GS, Nikfarjam M. Pancreas. (2015) 44:363-9..

Antibody Recognition of Shiga Toxins (Stxs): Computational Identification of the Epitopes of Stx2 Subunit A to the Antibodies 11E10 and S2C4, Jiao Y, Legge FS, Zeng X, Treutlein HR, Zeng J PLoS ONE (2014). Vol 9, e88191

A novel class of anti cancer compounds which target the actin cytoskeleton of tumor cells, Stehn J, Haass NK, Bonello T, Desouza N, Kottyan G, Treutlein HR, Zeng J, Nascimento PRBB, Sequeira VB, Tanya L. Butler TL, Allanson M, Fath T, Hill TA, McCluskey A, Schevzov G, Palmer SJ, Hardeman EC, Winlaw D, Reeve VE, Dixon I, Weninger W, Cripe TP, Gunning PW. Cancer Research (2013) vol. 73, Page 5169

Phenyl amino pyrmidines as inhibitors of Janus kinases (JAKs), Christopher J. Burns, David G. Bourke, Laura Andrau, Xianyong Bu, Sue Charman, Andrew C. Donohue, Emmanuelle Fantino, John T. Feutrill, Max Joffe, Marcel R. King, Margarita Kurek, Michelle Farrugia, Tracy L. Nero, Thao Nguyen, James T. Palmer, Ian Phillips, David Shackleford, Harrison Sikanyika, Michelle Styles, Stephen Su, Herbert Treutlein, Jun Zeng, Andrew F. Wilks, Bioorganic & Medicinal Chemistry Letters, 19 (2009) Vol 19, Page 5887

Discovery of 2-(a-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS, Christopher J. Burns, Michael F. Harte, Xianyong Bu, Emmanuelle Fantino, Marilena Giarrusso, Max Joffe, Margarita Kurek, Fiona S. Legge, Pasquale Razzino, Stephen Su, Herbert Treutlein, Soo San Wan, Jun Zeng, Andrew F. Wilks, Bioorganic & Medicinal Chemistry Letters (2009) Vol 19 , Page 1206

Mini-review: computational design of inhibitors that target protein surfaces, Jun Zeng, Comb. Chem. High Throughput Screen. (2000) Vol 3 , Page 355